Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.

Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG.

Can J Cardiol. 2011 Jul-Aug;27(4):523.e11-5. doi: 10.1016/j.cjca.2010.12.064. Epub 2011 Jun 12. English, French.

PMID:
21664100
[PubMed - indexed for MEDLINE]
2.

Economic analysis of palivizumab in infants with congenital heart disease.

Yount LE, Mahle WT.

Pediatrics. 2004 Dec;114(6):1606-11.

PMID:
15574622
[PubMed - indexed for MEDLINE]
3.

Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.

Chang RK, Chen AY.

Pediatr Cardiol. 2010 Jan;31(1):90-5. doi: 10.1007/s00246-009-9577-0. Epub 2009 Nov 14.

PMID:
19915892
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Nuijten MJ, Wittenberg W, Lebmeier M.

Pharmacoeconomics. 2007;25(1):55-71.

PMID:
17192118
[PubMed - indexed for MEDLINE]
5.

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.

Pediatrics. 2004 Dec;114(6):1612-9.

PMID:
15574623
[PubMed - indexed for MEDLINE]
6.

Cost effectiveness of palivizumab in children with congenital heart disease in Germany.

Nuijten M, Lebmeier M, Wittenberg W.

J Med Econ. 2009;12(4):301-8. doi: 10.3111/13696990903347172.

PMID:
19811110
[PubMed - indexed for MEDLINE]
7.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.

PMID:
14654627
[PubMed - indexed for MEDLINE]
8.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.

Clin Ther. 2000 Nov;22(11):1357-69.

PMID:
11117660
[PubMed - indexed for MEDLINE]
9.

Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Fenton C, Scott LJ, Plosker GL.

Paediatr Drugs. 2004;6(3):177-97.

PMID:
15170364
[PubMed - indexed for MEDLINE]
10.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
[PubMed - indexed for MEDLINE]
11.
12.

[Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].

Hascoet JM, Fagnani F, Charlemagne A, Vieux R, Rozé JC, Bendjenana H.

Arch Pediatr. 2008 Dec;15(12):1739-48. doi: 10.1016/j.arcped.2008.09.024. Epub 2008 Nov 5. French.

PMID:
18990549
[PubMed - indexed for MEDLINE]
13.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.

Pediatrics. 2003 Dec;112(6 Pt 1):1447-52.

PMID:
14654628
[PubMed - indexed for MEDLINE]
14.

The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.

Rackham OJ, Thorburn K, Kerr SJ.

Cardiol Young. 2005 Jun;15(3):251-5.

PMID:
15865826
[PubMed - indexed for MEDLINE]
15.

Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

Warren A, Langley JM, Thomas W, Scott J.

Can J Cardiol. 2007 May 1;23(6):463-6. Erratum in: Can J Cardiol. 2010 Jan;15(1):22.

PMID:
17487291
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.

Nuijten M, Lebmeier M, Wittenberg W.

J Med Econ. 2009;12(4):291-300. doi: 10.3111/13696990903316961.

PMID:
19811111
[PubMed - indexed for MEDLINE]
17.

Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.

Prescott WA Jr, Doloresco F, Brown J, Paladino JA.

Pharmacoeconomics. 2010;28(4):279-93. doi: 10.2165/11531860-000000000-00000. Review.

PMID:
20131925
[PubMed - indexed for MEDLINE]
18.

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM; Cardiac Synagis Study Group.

J Pediatr. 2003 Oct;143(4):532-40.

PMID:
14571236
[PubMed - indexed for MEDLINE]
19.

Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.

Meberg A, Bruu AL.

Acta Paediatr. 2006 Apr;95(4):404-6.

PMID:
16720485
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk